Gazyva

Chemical Nameobinutuzumab
Dosage FormInjection (intravenous; 1,000 mg/40 mL (25 mg/mL))
Drug ClassMonoclonal antibodies
SystemBlood
CompanyGenetech Inc.
Approval Year2013

Indication

  • Used in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia.
  • Used in combination with bendamustine followed by gazyva monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen.
  • Used in combination with chemotherapy followed by gazyva monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.
Last updated on 4/27/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Gazyva (obinutuzumab) Prescribing Information2013Genentech Inc., South San Francisco, CA